- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07599189
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients (AROMA-MS)
Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.
The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.
The main questions it aims to answer are:
- Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?
- What medical problems do participants have when using essential oil aromatherapy?
Researchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.
Participants will:
- Use essential oil aromatherapy or a placebo oil every day for 6 weeks
- Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day
- Fill out quality of life questionnaires at the beginning and end of the study
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Zitouni-Nourine Saida Hanane
- Telefonnummer: +213556623080
- E-mail: zitouni.saida@univ-oran1.dz
Studiesteder
-
-
-
Oran, Algeriet
- Zitouni-Nourine Saida Hanane
-
-
Oran Province
-
Oran, Oran Province, Algeriet, 31000
- Aboubakr abdelmadjid
-
Kontakt:
- Aboubakr Abdelmadjid, Professor
- Telefonnummer: (+213) 041 70 50 92
- E-mail: contact@ehuoran.dz
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Confirmed diagnosis of Multiple Sclerosis (any form)
- Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening
- Age between 18 and 65 years
- Willing and able to provide written informed consent
- Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period
Exclusion Criteria:
- Active urinary tract infection confirmed by urine culture at screening
- Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)
- Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary
- Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application
- Pregnancy, breastfeeding, or planning to become pregnant during the study period
- Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires
- Current use of an indwelling urinary catheter or practice of intermittent self-catheterization
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Essential Oil Aromatherapy Group
|
This intervention consists of a standardized topical blend of Lavender (Lavandula angustifolia) at 3% and Rosemary (Rosmarinus officinalis) at 2%, diluted in apricot kernel oil as a carrier.
The blend was formulated to target neurogenic lower urinary tract symptoms in patients with multiple sclerosis, based on the antispasmodic properties of Lavender and the neuromodulatory and anti-inflammatory properties of Rosemary.
The essential oils used are batch-controlled for chemical purity and concentration.
The blend is applied topically via gentle circular massage on the lower abdomen, for a total duration of 6 consecutive weeks.
This specific combination, route of administration, and target population distinguish this intervention from other aromatherapy studies that have used single oils, inhalation methods, or non-neurological populations.
|
|
Placebo komparator: Placebo Oil Group
|
This intervention consists of pure Apricot Kernel oil, used as an inert placebo comparator.
The placebo oil contains no active essential oils or therapeutic compounds.
It is identical to the experimental intervention in terms of appearance, color, viscosity, volume, packaging, and method of application, ensuring effective masking of participants and outcome assessors.
The placebo oil is applied topically via gentle circular massage on the lower abdomen, for a total duration of 6 consecutive weeks, mirroring exactly the administration protocol of the experimental arm.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overactive Bladder Symptom Score (OABSS)
Tidsramme: Baseline, and Week 6
|
Overactive Bladder Symptom Score (OABSS) (Overactive Bladder Symptom Score) Scale range: minimum 0 - maximum 15. Higher scores indicate a worse outcome (greater severity of overactive bladder symptoms). [Time Frame: Baseline and Week 6] |
Baseline, and Week 6
|
|
Qualiveen questionnaire
Tidsramme: Baseline and Week 6
|
Qualiveen - Urinary Disorder-Specific Quality of Life Questionnaire (Qualiveen, Domain 1: "Bother with Limitations") Scale range: minimum 0 - maximum 4 per item (9 items, total domain score = sum of items ÷ 9). Higher scores indicate a worse outcome (greater bother related to urinary problems). [Time Frame: Baseline and Week 6] |
Baseline and Week 6
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Vandladningsforstyrrelser
- Urologiske manifestationer
- Demyeliniserende autoimmune sygdomme, CNS
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Urinblæresygdomme
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Ufrivillig vandladning
- Multipel sclerose
- Nedre urinvejssymptomer
- Urinblære, neurogen
Andre undersøgelses-id-numre
- UO1-HE-SEP-URO-2025-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sklerose (MS)
-
GeNeuro Innovation SASAfsluttetMultipel sklerose (MS) | Klinisk isoleret syndrom (CIS) | Sekundær progressiv MS | Primær progressiv MS | Relapserende-Remitterende MSFrankrig, Spanien, Schweiz
-
Mohamed Moshref abd alsattarIkke rekrutterer endnu
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse...AfsluttetSund og rask | Klinisk isoleret syndrom | Multipel sklerose (MS) | Radiologisk isoleret syndrom | Multipel sklerose (MS) Relapsing Remitting | Multipel sklerose (MS) Primær progressiv | Multipel sklerose (MS) Sekundær progressivMonaco
-
University of California, San FranciscoGenentech, Inc.RekrutteringMultipel sclerose | MS (multipel sklerose) | FRK | Multipel sklerose (MS) - Relapsing-remitting | Multipel sklerose (MS) Primær progressiv | Multipel sklerose (MS) Sekundær progressivForenede Stater
-
University of MiamiNational Multiple Sclerosis Society; CerecinAfsluttetRecidiverende remitterende MS | Sekundær progressiv MS | Primær progressiv MSForenede Stater
-
German University in CairoAfsluttetMultipel sklerose (MS) - Relapsing-remittingEgypten
-
Moein AminNovartis PharmaceuticalsIkke rekrutterer endnuMultipel sklerose (MS) - Relapsing-remitting | Multipel sklerose (MS) Primær progressiv | Multipel sklerose (MS) Sekundær progressivForenede Stater
-
BayerAfsluttetRelapsing Remitting MS (RRMS) | Sekundær progressiv MS (SPMS)Frankrig, Tyskland, Korea, Republikken, Saudi Arabien, Spanien, Taiwan, Tjekkiet, Italien, Jordan, Libanon, Kalkun, Israel, Portugal, Holland, Iran, Islamisk Republik
-
BiogenAfsluttetTilbagevendende former for MSForenede Stater
-
Centre Hospitalier Universitaire de NiceAfsluttetMS KRONISK PROGRESSIVFrankrig
Kliniske forsøg med Essential Oil Blend (Lavender, Rosemary)
-
China Medical University HospitalRekrutteringMild kognitiv svækkelseTaiwan
-
Inonu UniversityAfsluttetUniversitetsstuderendeKalkun